Head to Head Contrast: PROCEPT BioRobotics (NASDAQ:PRCT) vs. Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences (NASDAQ:PLSE) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Pulse Biosciences and PROCEPT BioRobotics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$700,000.00	1,566.52	-$42.21 million	N/A	N/A
PROCEPT BioRobotics	$249.12 million	12.16	-$105.90 million	($1.70)	-32.22

Pulse Biosciences has higher earnings, but lower revenue than PROCEPT BioRobotics.

Profitability

This table compares Pulse Biosciences and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-96.89%	-74.83%
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%

Risk & Volatility

Pulse Biosciences has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Insider & Institutional Ownership

76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pulse Biosciences and PROCEPT BioRobotics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	0	0	0	0	0.00
PROCEPT BioRobotics	0	1	6	0	2.86

PROCEPT BioRobotics has a consensus target price of $90.00, suggesting a potential upside of 64.32%. Given PROCEPT BioRobotics’ stronger consensus rating and higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Pulse Biosciences.

Summary

PROCEPT BioRobotics beats Pulse Biosciences on 7 of the 12 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.